Background
==========

Induction and persistence of vaccine induced antibodies among recipients of HIV vaccines may pose a diagnostic challenge. We investigated the performance and usefulness of rapid tests for the detection of HIV antibodies among healthy HIV-uninfected people previously enrolled in a phase I HIV vaccine trial in Kigali, Rwanda.

Methods
=======

Between September 2005 and May 2006, 57 healthy, HIV-uninfected adult volunteers (36 males and 21 females) were enrolled in a phase-I, randomized, placebo-controlled HIV vaccine trial at Projet San Francisco in Kigali, Rwanda. At the end of the trial and after unblinding, all volunteers were asked to participate in a long-term follow-up study for continuous clinical and immunological evaluation. HIV testing using three rapid tests (Abbott Determine™ HIV1-2, Trinity Biotech Capillus™ HIV-1/HIV-2 and Trinity Biotech Uni-GoldTM HIV) and an ELISA test (Bio-Mérieux Vironostika HIV Uniform II Ag/Ab) was performed every three months.

Results
=======

Of the 57 volunteers enrolled in the trial, 13 received placebo, 13 received one dose of a recombinant HIV-1 adenoviral type 5 vector vaccine (rAd5), and 31 received 3 doses of an HIV-1 DNA plasmid vaccine followed by one dose of rAd5. Of these 44 vaccine recipients, 41 produced HIV antibodies during the trial period. After 18 to 24 months of follow-up, 32 volunteers still test HIV-positive on the ELISA test, but only one volunteer tested persistently HIV positive using HIV rapid tests.

Conclusion
==========

Most vaccine recipients produced HIV antibodies that have persisted for at least two years. These vaccine-induced antibodies are predominantly detected by a commercial ELISA test, and not by the three HIV rapid tests that were evaluated. This study suggests that HIV rapid tests can be very useful in the long-term follow-up of HIV vaccine recipients.
